Search
SOLACI Congress
HomeStructural heart diseaseValvular Aortic Valve

Valvular Aortic Valve

View Category
Structural heart disease

ENVISAGE-TAVI AF Trial: What Anticoagulant Should We Use?

Between 15% and 30% of patients undergoing TAVR present atrial fibrillation. Many of them have suffered ischemic...
Dr. Carlos Fava -
Learn More
Mitral valve

Evolution at 1 Year for the PARTNER 3 Mitral Valve-in-Valve Study

At present, the structural failure of mitral bioprostheses due to their deterioration poses a significant challenge. While...
Dr. Carlos Fava -
Learn More
Mitral valve

Edge-to-Edge Tricuspid Valve Repair 3-Year Follow Up

Tricuspid regurgitation (TR) is associated to fatigue and peripheral edema, and medical treatment with diuretics has a...
Dr. Carlos Fava -
Learn More
Antithrombotic Anticoagulants

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral...
Dr. Carlos Fava -
Learn More
Structural heart disease

MATTERHORN: Edge-to-Edge Repair vs. Surgery for Secondary Mitral Valve Regurgitation

Frequently associated with hospitalization for cardiac failure and mortality, secondary mitral valve regurgitation (MR) is the most...
Dr. Carlos Fava -
Learn More
Structural heart disease

Severe Aortic Stenosis in Bicuspids: Promising Self-Expanding Valve Outcomes at 3 years

Bicuspid aortic valves represent a significant challenge in TAVR because of its anatomical complexity and the presence...
Dr. Carlos Fava -
Learn More
Other

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known...
solaci -
Learn More
Structural heart disease

Myocardial Damage in MAC

Mitral annulus calcification (MAC) affects between 8% and 23% of the population. It is more common in...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

Dr. Omar Tupayachi - 0
While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Dr. Andrés Rodríguez - 0
Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Dr. Omar Tupayachi - 0
Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Institutional News

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy